ProNAi Therapeutics, Inc. has signed a supply agreement with Polymun Scientific GmbH, an Austrian contract biopharmaceutical developer, to manufacture the company’s PNT2258 DNAi-based cancer therapeutic. Under the terms of the agreement, Polymun will use its cross-flow injector technology to manufacture ProNAi’s liposome-formulated lead drug candidate, which is in the final stages of preclinical toxicology testing. ProNAi plans to submit an IND for PNT2258 later this year. ...